KALRAY
Kalray (Euronext Growth Paris: ALKAL), a leading provider in the new generation of processors specialized in Intelligent Data Processing from Cloud to Edge, today unveils its new K200-LP™ acceleration card. K200-LP™ is a new member of Kalray’s fully programmable multi-purpose acceleration card family, based on its unique MPPA® processor, and offering an unprecedented level of performance and targeting the booming NVMe based storage market as its first implementation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615006166/en/
The explosion of data, driven by demanding services and applications using AI and data analytics, is putting a lot of pressure on Cloud and Edge Data Center’s networking and storage to feed the demanding compute intensive resources. The primary needs are to reduce latency, enhance bandwidth and IOPs1 performance as well as offloading host CPUs, at best cost.
Data centers are looking for solutions that enable high performance, low power, cost effectiveness and openness to scale and match demand on data availability. The K200-LP™ acceleration card is Kalray’s solution to address these exacting demands for their data center customers.
Eric Baissus, President and CEO of Kalray, said: “We are proud to unveil our new K200-LP™ acceleration card, based on our MPPA® processor. This family of Ethernet/PCIe acceleration cards are natively capable of managing multiple workloads with no bottleneck to enable smarter, more efficient, and energy-wise applications on Cloud and Edge data centers. To address the new generation of storage array solutions for Cloud and Edge, K200-LP™ is a game changer solution in terms of performance per Watt and per dollar .”
To improve and optimize overall IT infrastructures, the industry has moved increasingly towards disaggregated storage. Put simply, separating compute resources and storage resources.
1 IOPS is the numbers of Input/Output operations per second and is a performance measurement used to characterize computer storage devices.
Most advanced All-Flash-Array solutions today use multiple adapter cards around a x86 that runs storage services. Kalray manages to run all the critical functions of a disaggregated storage appliance on one single chip: the Kalray MPPA® processor. Advanced Data Processing Units (DPU) like MPPA® and associated acceleration cards can run, efficiently and on a cost-optimized manner versus traditional x86, new protocols such as NVMe and NVMe-over-Fabric to access and unleash the full capability of SSDs wherever they are located in the Data Center as if there were locally attached.
Whereas the industry has defined a new NVMe protocol to support the latest generation of ultra-fast storage devices, existing traditional technologies are not capable of exposing the full capability of NVMe-based SSDs. Kalray’s K200-LP™ smart storage card has been built from the ground-up to support those breaking through data protocols. Based on Kalray MPPA’s processor, K200-LP™ is also the perfect solution for storage array appliance makers and cloud service providers, to build their next generation of storage appliances in terms of performance per Watt per $.
Kalray’s K200-LP™ acceleration card is a low-profile, 2x 100GB ethernet, PCIe Gen4 card that can deliver more than 2 MIOPS and 12 GB/s per card (both RoCE and TCP) with a latency as low as 30 microseconds. K200-LP™ has been developed by Kalray and is manufactured by Taiwanese Wistron, one of the largest manufacturers of electronic cards and data center servers in the world.
Kalray’s K200-LP™ smart storage card and associated tools are available now.
ABOUT KALRAY
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is a fabless semiconductor company, leading provider in a new generation of processors specialized in Intelligent Data Processing from Cloud to Edge. Kalray MPPA® Intelligent Processors are able to capture and analyze on the fly massive data flows, and interact in real time with the outside world. These processors are capable of running demanding AI algorithms and simultaneously a wide set of different processing and control tasks such as intensive mathematical algorithms, signal processing, network or storage software stacks. Kalray’s Intelligent Processors can be deployed in fast-growing sectors from Cloud to Edge: modern data centers, 5G telecom networks, autonomous vehicles, healthcare equipment, industry 4.0, drones and robots… Kalray’s offering includes processors, acceleration cards and a software suite, for a broad spectrum of customers such as next generation data center equipment manufacturers and service providers, system integrators and consumer product manufacturers such as car makers. Founded in 2008 as a spin-off of CEA French lab, Kalray counts among its investors: Alliance Venture (Renault-Nissan-Mitsubishi), Safran, NXP Semiconductors, CEA and Bpifrance. Read more at: www.kalrayinc.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615006166/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom